Powered by

Cleave Therapeutics Appoints Amy Burroughs Chief Executive Officer and Completes $12 Million Equity Financing

Aug 06, 2019 - Business Wire
Board and Executive Moves-Investments

Cleave Therapeutics, Inc. (formerly Cleave Biosciences), a biopharmaceutical company focused on protein homeostasis and stress pathways in cancer and neurodegeneration, has appointed industry veterans Amy Burroughs as chief executive officer and Scott Harris as chief operating officer. Cleave also announced the closing of a $12 million financing to advance CB-5339, its second-generation, IND-ready, valosin-containing protein (VCP)/p97 inhibitor through early clinical development. The financing w...